Estrogen-producing tumors are growths that secrete abnormally high levels of estrogen, and they can arise in the ovaries, adrenal glands, or testes. Because estrogen affects so many tissues throughout the body, these tumors often announce themselves through surprising changes: unexpected vaginal bleeding years after menopause, breast enlargement in a man, or early puberty in a young child. Despite their dramatic effects, many of these tumors are rare enough that even experienced clinicians can miss the diagnosis on the first pass.
Where These Tumors Come From
Most estrogen-producing tumors originate in organs that already have some role in hormone production. The ovary is the most common site. A group called sex cord-stromal tumors, which includes granulosa cell tumors and thecomas, accounts for the majority of estrogen-secreting ovarian masses. Granulosa cell tumors make up roughly 2 to 5 percent of all ovarian cancers, but they punch above their weight in clinical importance because they churn out hormones that affect distant organs.
The adrenal glands are a rarer source. Estrogen-secreting adrenocortical carcinomas represent only about 1 to 2 percent of all adrenocortical carcinomas, and cases in women are even scarcer, with only a handful described in the medical literature.1PubMed Central. Estrogen-secreting adrenocortical tumor in a postmenopausal woman: a challenging diagnosis In men, testicular tumors such as Leydig cell tumors and large cell calcifying Sertoli cell tumors can also produce estrogen, either directly or by converting androgens into estrogen through an enzyme called aromatase.
Aromatase is the key player in most of these tumors. It converts androgens like testosterone into estrogens like estradiol.2PubMed Central. Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells Normally, aromatase activity is present at modest levels in the ovaries, testes, fat tissue, skin, and brain. Certain cancers of the breast, endometrium, and ovary overexpress aromatase and produce estrogen locally, creating a kind of hormonal microenvironment that fuels their own growth.3PubMed Central. Aromatase excess in cancers of breast, endometrium and ovary In estrogen-producing tumors specifically, the aromatase pathway is only part of the story. In some breast tumors, a second enzyme pathway using estrone sulfatase produces roughly ten times as much estrogen as aromatase does, meaning the tumor has more than one way to keep its estrogen supply flowing.4The Journal of Clinical Endocrinology & Metabolism. In Situ Estrogen Production via the Estrone Sulfatase Pathway in Breast Tumors: Relative Importance versus the Aromatase Pathway
Signs in Women
The symptoms a woman experiences depend heavily on whether she has already gone through menopause. In premenopausal women, excess estrogen from a tumor can cause irregular periods, unusually heavy bleeding, or breast tenderness. These symptoms overlap with many benign conditions, which is one reason these tumors often take a while to identify.
In postmenopausal women, the picture is more distinctive. Any vaginal bleeding after menopause demands investigation, and an estrogen-producing tumor is one of the possible causes. Bleeding triggered by excess estrogen tends to stop once the hormone source is removed, while bleeding caused by endometrial cancer tends to persist or recur.5PubMed. Postmenopausal vaginal bleeding during estrogen therapy Still, the standard recommendation is that all postmenopausal bleeding be evaluated with sampling of the uterine lining, because relying on the pattern of bleeding alone is not reliable enough to rule out cancer.
An estrogen-secreting adrenal tumor in a postmenopausal woman is especially tricky to diagnose. The adrenal gland is not the first place clinicians look when a woman presents with signs of excess estrogen, and only a handful of such cases appear in the literature.1PubMed Central. Estrogen-secreting adrenocortical tumor in a postmenopausal woman: a challenging diagnosis When an adrenal tumor does produce feminizing effects, it is considered nearly diagnostic of malignancy, and these tumors tend to be larger and carry a worse prognosis than non-hormone-producing adrenal cancers.
Signs in Men and Boys
Estrogen-producing tumors in males tend to be noticed faster precisely because their effects are so unexpected. An adult man with a feminizing tumor may develop breast tissue growth (gynecomastia), chest tenderness, fatigue, and erectile dysfunction. One well-documented case involved a 44-year-old man who went to his doctor with exactly those complaints; testing eventually revealed an estrogen-secreting adrenal adenoma.6PubMed Central. Benign Feminizing Adrenal Tumor in an Adult Male After laparoscopic removal of the adenoma, his symptoms improved and his hormone levels returned to normal within six months.
In prepubertal boys, estrogen-producing tumors can trigger signs that mimic early puberty but with a feminizing twist. A boy with a Sertoli cell tumor of the testis, for instance, may present with gynecomastia, rapid growth, and bone that matures faster than it should for his age.7The Journal of Clinical Endocrinology & Metabolism. Use of Aromatase Inhibitors in Large Cell Calcifying Sertoli Cell Tumors: Effects on Gynecomastia, Growth Velocity, and Bone Age Historical case reports going back decades describe children as young as five with pronounced changes toward opposite-sex characteristics driven by adrenal tumors.8The Journal of Clinical Endocrinology & Metabolism. A FEMINIZING ADRENAL TUMOR CAUSING GYNECOMASTIA IN A BOY OF FIVE YEARS CONTRASTED WITH A VIRILIZING TUMOR IN A FIVE-YEAR-OLD GIRL In both adults and children, these symptoms typically reverse once the tumor is removed, though advanced bone age in children cannot be fully undone.
Blood Markers That Help Pin Down the Diagnosis
Elevated estradiol on a routine hormone panel can raise suspicion, but it is not specific enough on its own. For ovarian granulosa cell tumors, two serum markers stand out: inhibin B and anti-Müllerian hormone (AMH). Both are produced by granulosa cells, and both tend to rise well before the tumor becomes clinically obvious. In one study, AMH and inhibin levels became elevated at least 11 months before a recurrence could be detected on imaging or physical exam.9PubMed. Antimüllerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum alpha-inhibin and estradiol
The two markers perform similarly in terms of sensitivity. AMH has been shown to be about 92 percent sensitive and 81 percent specific for detecting a granulosa cell tumor that is large enough to see, and combining both markers improves detection of recurrent disease beyond what either one achieves alone.10PubMed. The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors–A comparative study with inhibin B AMH is generally considered more specific than inhibin because inhibin can also rise in some non-granulosa-cell ovarian tumors, such as mucinous epithelial tumors.11PubMed. The role of inhibins B and antimüllerian hormone for diagnosis and follow-up of granulosa cell tumors In practice, most specialists monitor both.
For adrenal estrogen-producing tumors, the workup looks different. The hormonal panel focuses on serum estradiol, estrone, DHEA-sulfate, and cortisol, along with imaging of the adrenal glands. A sharp elevation of estradiol in a postmenopausal woman or in a man, combined with an adrenal mass on a CT scan, forms a strong circumstantial case even before pathology confirms the diagnosis.
Imaging and What It Can (and Cannot) Show
Most ovarian masses can be identified during a pelvic exam or with vaginal ultrasound, which can detect very small lesions that are not palpable. For tumors outside the ovary, CT or MRI can pick up adrenal or other abdominal masses. The challenge is that sex cord-stromal tumors of the ovary have a wide range of appearances. They can look like large multicystic masses, small solid nodules, or anything in between, which makes it difficult to diagnose them by imaging alone.12PubMed. Sex cord-stromal and steroid cell tumors of the ovary
That said, some clinical and radiologic clues can narrow the field. A predominantly fibrous-appearing mass on ultrasound or MRI may suggest a fibrothecoma. A large hemorrhagic cystic mass in a child with early puberty points toward a juvenile granulosa cell tumor. And certain genetic syndromes are associated with specific tumor types: Peutz-Jeghers syndrome with sex cord tumors with annular tubules, and Ollier disease or Maffucci syndrome with juvenile granulosa cell tumors.12PubMed. Sex cord-stromal and steroid cell tumors of the ovary Knowing a patient’s syndrome history can sometimes short-circuit a long diagnostic workup.
Confirming the Tumor Under the Microscope
The definitive diagnosis comes from pathology. Granulosa cell tumors are divided into adult-type and juvenile-type based on their appearance under the microscope. The adult type is far more common and has a near-universal genetic calling card: about 97 percent of adult-type granulosa cell tumors carry a specific mutation in the FOXL2 gene, a transcription factor essential for granulosa cell development.13New England Journal of Medicine. Mutation of FOXL2 in granulosa-cell tumors of the ovary This mutation is a single letter change in the gene’s code (C134W), and it is remarkably specific. It was absent from 329 unrelated ovarian or breast tumors tested in the same landmark study. Only about 10 percent of juvenile-type granulosa cell tumors carry the same mutation, which helps pathologists distinguish the two types in ambiguous cases.
Immunohistochemistry complements the genetic test. Granulosa cell tumors typically stain positive for inhibin, calretinin, and WT1.14PubMed. Composite FOXL2 Mutation-positive Adult Granulosa Cell Tumor and Serous Borderline Tumor of the Ovary This panel helps separate them from more common epithelial ovarian cancers, which look different under the microscope but can occasionally overlap in presentation. The FOXL2 mutation was also found in about 21 percent of thecomas, underscoring some biological overlap between these tumor types.13New England Journal of Medicine. Mutation of FOXL2 in granulosa-cell tumors of the ovary
The Danger of Chronic Estrogen Exposure to the Uterus
One of the most important consequences of an estrogen-producing tumor is what it does to the uterine lining. Chronic exposure to estrogen that is not counterbalanced by progesterone causes the endometrium to proliferate abnormally, a condition called endometrial hyperplasia.15PubMed Central. Endometrial hyperplasia as a risk factor of endometrial cancer Left unchecked, this can progress to endometrial cancer. The relationship between unopposed estrogen and endometrial cancer is one of the most well-established links in gynecologic oncology: the more estrogen without progesterone, and the longer the exposure, the higher the risk.16PubMed. Progestogen deficiency and endometrial cancer risk
This means that when a woman is found to have an estrogen-producing ovarian tumor, her uterus needs evaluation too. Endometrial biopsy or sampling is standard to check for hyperplasia or early cancer. When hyperplasia is present, it can be treated with progestins if the patient wants to preserve fertility. If atypical cells are found, the clinical decision becomes more complex, because the available markers do not reliably predict which cases of atypical hyperplasia will progress to cancer.17European Journal of Cancer Prevention. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures In such cases, hysterectomy is often recommended alongside removal of the tumor.
Blood Clots as an Underappreciated Risk
Excess estrogen does not just affect the reproductive tract. High estrogen levels shift the blood’s clotting balance in a prothrombotic direction. Estrogen increases levels of several clotting factors, including factors II, VII, VIII, and X, as well as von Willebrand factor and fibrinogen, while also modulating how platelets activate and clump together.18PubMed. Hyperestrogenemia resulting from a granulosa cell tumor and causing pulmonary thromboembolism: a case report The result can be life-threatening blood clots. In one reported case, a 59-year-old postmenopausal woman presented to the emergency room with shortness of breath and a swollen abdomen; she was found to have both a large estrogen-producing ovarian tumor and a pulmonary embolism.
Recent research has begun to map the mechanism more precisely. High estradiol concentrations appear to activate platelets through a signaling pathway that increases the release of ADP, a molecule that recruits more platelets to a growing clot. In animal models, the antiplatelet drug clopidogrel blocked this estrogen-driven enhancement of clot formation.19PubMed. High-concentration estradiol promotes platelet activation and thrombosis through Src-ADP axis Clinicians managing patients with estrogen-producing tumors should keep thrombotic risk on their radar, particularly in the perioperative period when the combination of surgery and high estrogen creates a perfect storm for clot formation.
Treatment Approaches
Surgery is the first-line treatment for virtually all estrogen-producing tumors. For ovarian granulosa cell tumors caught at an early stage in a young woman who wants to preserve fertility, a unilateral salpingo-oophorectomy (removing the affected ovary and its fallopian tube) is often sufficient. For older women or more advanced disease, the standard approach is a total hysterectomy with bilateral salpingo-oophorectomy, combined with thorough surgical staging. For adrenal tumors, laparoscopic adrenalectomy is the approach for smaller tumors, while larger or invasive adrenal carcinomas may require open surgery with wide margins.
Hormonal therapy plays a supporting role, especially for recurrent disease. Granulosa cell tumors respond to a variety of hormonal manipulations, including aromatase inhibitors, which block the enzyme that drives estrogen production.20PubMed Central. Aromatase inhibitors in gynecologic cancers Combined endocrine blockade using aromatase inhibitors alongside other hormonal agents has also shown promise in case reports and small series. For prepubertal boys with Sertoli cell tumors, aromatase inhibitors have been used to manage gynecomastia, slow down accelerated growth, and delay premature bone maturation.7The Journal of Clinical Endocrinology & Metabolism. Use of Aromatase Inhibitors in Large Cell Calcifying Sertoli Cell Tumors: Effects on Gynecomastia, Growth Velocity, and Bone Age Chemotherapy is reserved for advanced or aggressive cases where surgery and hormonal therapy are not sufficient.
Why Long-Term Follow-Up Matters So Much
Granulosa cell tumors are notorious for recurring years or even decades after the initial treatment. This is one of their defining characteristics and the reason surveillance cannot be casually discontinued. One study of molecularly confirmed adult-type granulosa cell tumors recommended active follow-up for 10 to 15 years after primary diagnosis because recurrences can develop late, show no symptoms, and appear in multiple locations throughout the abdomen.21PubMed. Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors
European guidelines recommend pelvic exams and tumor marker checks every three months for the first two years, then every six months from the third year onward. For women who underwent fertility-sparing surgery and still have one ovary, a pelvic ultrasound every six months is standard. CT scans of the abdomen and pelvis are added based on clinical suspicion rather than on a rigid schedule.22PubMed Central. Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary Monitoring AMH and inhibin B at each visit is helpful because, as noted earlier, these markers can flag a recurrence many months before imaging shows anything visible.
Estrogen-Producing Tumors in Breast Cancer Biology
While most of this article focuses on tumors that secrete estrogen into the bloodstream, a related phenomenon occurs locally within breast tumors. Many breast cancers overexpress aromatase and produce their own estrogen supply right inside the tumor tissue, feeding their own growth through a self-sustaining hormonal loop.3PubMed Central. Aromatase excess in cancers of breast, endometrium and ovary The estrogen produced this way acts in a very localized fashion rather than raising blood estrogen levels the way an ovarian or adrenal tumor does. This is why a postmenopausal woman can have an estrogen-driven breast cancer and still have low systemic estrogen on blood tests.
The discovery of this local estrogen production is what made aromatase inhibitors a cornerstone of estrogen-receptor-positive breast cancer treatment. Blocking aromatase starves the tumor of its self-produced estrogen. Interestingly, in hormone-dependent breast cancers, the estrone sulfatase pathway produces substantially more local estrogen than the aromatase pathway, suggesting that combination therapies targeting both enzyme systems might one day be more effective than aromatase inhibitors alone.4The Journal of Clinical Endocrinology & Metabolism. In Situ Estrogen Production via the Estrone Sulfatase Pathway in Breast Tumors: Relative Importance versus the Aromatase Pathway Research into sulfatase inhibitors has been slow compared to aromatase inhibitor development, but the biological rationale remains compelling.